样式: 排序: IF: - GO 导出 标记为已读
-
Time is Money: Protected Time for Fellow Education Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-17 Alice M. Sheridan
An abstract is unavailable.
-
The Clinical Study of Kidney Stone Disease and the Value of Specificity Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-17 Alan C. Pao, Calyani Ganesan
An abstract is unavailable.
-
Did the SCORED Trial Get Extra Points for Kidney Outcomes? If So, It Is Not Obvious Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-17 Nupur Mistry, George L. Bakris
An abstract is unavailable.
-
Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-16 Robert A. Fletcher, William G. Herrington, Rajiv Agarwal, Kaitlin J. Mayne, Clare Arnott, Meg J. Jardine, Kenneth W. Mahaffey, Vlado Perkovic, Natalie Staplin, David C. Wheeler, Glenn M. Chertow, Hiddo J. L. Heerspink, Brendon L. Neuen
An abstract is unavailable. This article is available as a PDF only.
-
Association of Inflammatory Bowel Disease with Incident Immunoglobulin A Nephropathy Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-04-11 Takashin Nakayama, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Katsuhito Fujiu, Norifumi Takeda, Hiroyuki Morita, Norihiko Takeda, Akira Fukui, Takashi Yokoo, Hideo Yasunaga, Masaomi Nangaku, Kaori Hayashi
sing a large-scale epidemiological cohort. Methods We retrospectively analyzed 4,311,393 adults enrolled in the JMDC Claims Database (previously known as the Japan Medical Data Center database), a nationwide epidemiological database in Japan. The definitions of IgA nephropathy and inflammatory bowel disease (ulcerative colitis or Crohn’s disease) were based on International Classification of Diseases-10th
-
Calibration of Priority Points for Sensitization Status of Kidney Transplant Candidates in the United States Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-21 Jesse. D. Schold, Anat R. Tambur, Sumit Mohan, Bruce Kaplan
uld improve equity in access to transplantation for disadvantaged candidates. We sought to evaluate the effect of these weights using a contemporary cohort of adult US kidney transplant candidates. Methods We used the national Scientific Registry of Transplant Recipients to evaluate factors associated with sensitization using multivariable logistic models and rates of deceased donor transplantation
-
Non-Lupus Full House Nephropathy Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-26 Martina Uzzo, Andreas Kronbichler, Federico Alberici, Ingeborg Bajema
n non-lupus full house nephropathy nomenclature, clinical findings and outcomes. Methods: In a reiterative process, all identified terms for non-lupus full house nephropathy and other MeSH terms were searched in PubMed. Out of 344 results, 57 records published between 1982 and 2022 were included in the analysis. Clinical data of single patients from different reports were collected. Patients were classified
-
Associations between Different Antivirals and Hospital acquired Acute Kidney Injury in Adults with Herpes Zoster Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-26 Ruqi Xu, Qi Gao, Yuping Zhang, Yuxin Lin, Yanqin Li, Licong Su, Shiyu Zhou, Yue Cao, Peiyan Gao, Pingping Li, Fan Luo, Ruixuan Chen, Xiaodong Zhang, Sheng Nie, Xin Xu, the CRDS study Investigators
China Renal Data System (CRDS). We identified and staged AKI using patient-level serum creatinine data according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria. We compared the relative risks of hospital acquired AKI among patients treated with different antivirals using Cox proportional hazards models. Results: Among 3273 patients, 1480 (45%), 681 (21%), 489 (15%) and 623 (19%) were
-
Clinical Outcomes after a Kidney Stone Event in Kidney Transplant Recipients Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-14 Ganesan, Calyani, Liu, Sai, Montez-Rath, Maria, Leppert, John T., Pao, Alan C.
No abstract available
-
How We Treat Primary Hyperoxaluria Type 1 Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-18 Breeggemann, Matthew C., Harris, Peter C., Lieske, John C., Tasian, Gregory E., Wood, Kyle D.
No abstract available
-
The Future of the US Nephrology Workforce following the End of Affirmative Action Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-07 Deidra C. Crews
An abstract is unavailable.
-
KRT in Patients with AKI and Cirrhosis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-05 Sapna V. Shah, Mitra K. Nadim
An abstract is unavailable.
-
Different interdialytic intervals and cardiorespiratory fitness in patients undergoing hemodialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-26 Eva Pella, Aristi Boulmpou, Afroditi Boutou, Marieta P. Theodorakopoulou, Nasra Haddad, Antonios Karpetas, Panagiotis Giamalis, Aikaterini Papagianni, Christodoulos E. Papadopoulos, Vassilios Vassilikos, Pantelis Sarafidis
ssessed with cardiopulmonary exercise testing (CPET) between the end of the 2-day and the 3-day interdialytic interval. Methods: A total of 28 hemodialysis patients, randomized in two different sequences of evaluation underwent CPET and spirometry examination at the end of the 2-day and the 3-day intervals. The primary outcome was the difference in oxygen uptake at peak exercise [VO2peak(ml/kg/min)]
-
Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-26 Thomas Bais, Paul Geertsema, Martine G.E. Knol, Maatje D.A. van Gastel, Robbert J. de Haas, Esther Meijer, Ron T. Gansevoort, on behalf of the DIPAK Consortium
Included were patients with ≥1 height-adjusted total kidney volume (HtTKV) measurement and ≥3 estimated glomerular filtration rate (eGFR) values during ≥1 year follow-up. Mayo HtTKV class stability, kidney growth rates and eGFR decline rates were calculated. The observed eGFR decline was compared to predictions from the Mayo Clinic future eGFR equation. The future eGFR prediction equation was also
-
Cover Image Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-03-01 Bakis, Hugo
No abstract available
-
-
Combined Serologic and Genetic Risk Score and Prognostication of PLA2R-Associated Membranous Nephropathy Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-29 Hu, Xiaofan, Xu, Jing, Wang, Wei, Liu, Lili, Jing, Yuanmeng, Gao, Chenni, Yu, Xialian, Li, Yi, Lin, Li, Tong, Jun, Weng, Qinjie, Pan, Xiaoxia, Zhang, Wen, Ren, Hong, Li, Guisen, Kiryluk, Krzysztof, Chen, Nan, Xie, Jingyuan
Introduction: The aim of this study was to test whether a combined risk score based on genetic risk and serology can improve the prediction of kidney failure in PLA2R-associated primary membranous nephropathy. Methods: We performed a retrospective analysis of 519 biopsy-proven PLA2R-associated primary membranous nephropathy patients with baseline eGFR ≥ 25ml/min/1.73m2. The combined risk score was
-
Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients: A Randomized Placebo-Controlled Clinical Trial Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-27 Line A. Mortensen, Bente Jespersen, Anne Sophie L. Helligsoe, Birgitte Tougaard, Donata Cibulskyte-Ninkovic, Martin Egfjord, Lene Boesby, Niels Marcussen, Kirsten Madsen, Boye L. Jensen, Inge Petersen, Claus Bistrup, Helle C. Thiesson
ey transplant patients treated with calcineurin inhibitors. Methods: Randomized, placebo-controlled, double blind clinical trial including 188 prevalent kidney transplant patients. Patients were randomized to spironolactone or placebo for three years. Glomerular filtration rate was measured along with proteinuria and kidney fibrosis. The primary endpoint was change in measured glomerular filtration
-
Trends in Automated Peritoneal Dialysis Prescriptions in a Large Dialysis Organization in the United States Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-19 Harold E. Giles, Vidhya Parameswaran, Rachel Lasky, Linda Ficociello, Claudy Mullon, Dinesh K. Chatoth, Michael Kraus, Michael S. Anger
. The present analysis aimed to assess variations in PD prescriptions among incident automated PD (APD) patients who remain on PD for 120+ days. Methods: This retrospective analysis examined data from patients within a large dialysis organization that initiated PD with APD between 2015 and 2019. PD prescription data was described by calendar year, timing of PD, and residual renal function categories
-
RNA Interference as a Therapeutic Approach for Managing Hypertension Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-13 Jia Wei Tan, Vivek Bhalla
An abstract is unavailable. This article is available as a PDF only.
-
Fructokinase Inhibition to Prevent Kidney Disease Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-13 Ducloux, Didier
No abstract available
-
Dialysate Sodium Lowering in Maintenance Hemodialysis A Randomized Clinical Trial Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-13 Dana C. Miskulin, Hocine Tighiouart, Caroline M. Hsu, Daniel E. Weiner
to 140 mEq/L in low arm participants. The primary outcome was intradialytic hypotension (IDH). Secondary outcomes included dialysis disequilibrium symptoms, ER visits/hospitalizations, interdialytic weight gain, blood pressure (BP). Longitudinal changes across arms were analyzed using linear mixed regression. Results: Treatment to dialysate sodium 135 vs. 138 mEq/L was not associated with a difference
-
Preventive Pharmacological Therapy and Risk of Recurrent Urinary Stone Disease Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-12 Kumaran Arivoli, Autumn N. Valicevic, Mary K. Oerline, Ryan S. Hsi, Sanjeevkumar R. Patel, John M. Hollingsworth, Vahakn B. Shahinian
icians. This study aimed to evaluate the association between preventive pharmacological therapy (thiazide diuretics, alkali therapy, and uric acid lowering medications) and clinically significant urinary stone disease recurrence. Methods: Using data from the Veterans Health Administration, adults with an index episode of urinary stone disease from 2012 through 2019 and at least one urinary abnormality
-
Should Transplant Nephrology pursue recognition from the Accreditation Council for Graduate Medical Education (ACGME)? Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-06 Neeraj Singh, Prince M Anand, Gaurav Gupta, Deirdre Sawinski, Oren Fix, Deborah Adey, Enver Akalin, Carlos Zayas, Darshana Dadhania, Mona Doshi, Diane Cibrik, Mallika Gupta, Ronald Parsons, Nicolae Leca, Rowena Delos Santos, Beatrice P Concepcion, Angie G Nishio Lucar, Song Ong, Vikas Srinivasan Sridhar, Sandesh Parajuli, Mareena Zachariah, Shikha Mehta, Karim Soliman, Saed Shawar, Syed Ali Husain
understand immunology and organ rejection, have familiarity with peri-operative complications, and have the ability to manage the long-term effects of chronic immunosuppression. This skill set at the intersection of multiple disciplines necessitates additional training in Transplant Nephrology. Currently, there are more than 250,000 patients with a functioning kidney allograft and over 100,000 waitlisted
-
Embracing Complexity to Better Serve Pediatric Kidney Transplant Recipients Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-02-05 Lindsey M. Maclay, S. Ali Husain
An abstract is unavailable.
-
-
-
Pregnancy in Patients Receiving Home Dialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-29 Ghada Ankawi, Nishanta Tangirala, Shilpanjali Jesudason, Michelle A. Hladunewich
ntil after kidney transplantation. Pregnancy rates in women with advanced kidney failure or receiving dialysis remain low, and despite the improved outcomes in recent years, these pregnancies remain high risk for both mother and baby with high rates of preterm birth due to both maternal and fetal complications. However, with increased experience and advances in models of care, this paradigm may be
-
Closure of Dialysis Clinics in the US in 2021-2023 Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-23 Kamyar Kalantar-Zadeh, Dawn P. Edwards, David Henner, Daniel L Landry, Donald A Molony, Preethi Yerram, on behalf of the Medical Advisory Council of the National Forum of ESRD Networks
An abstract is unavailable. This article is available as a PDF only.
-
Effects of Vitamin D3 Supplementation on Incident Fractures by eGFR in VITAL Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 Hsu, Simon, Zelnick, Leila R., Buring, Julie E., Chou, Sharon H., Cook, Nancy R., D’Agostino, Denise, Hoofnagle, Andrew N., LeBoff, Meryl S., Lee, I-Min, Limonte, Christine P., Sesso, Howard D., Manson, JoAnn E., de Boer, Ian H.
No abstract available
-
Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 Gillian Divard, Olivier Aubert, Charlotte Debiais-Deschamp, Marc Raynaud, Valentin Goutaudier, Marta Sablik, Caroline Sayeg, Christophe Legendre, Julie Obert, Dany Anglicheau, Carmen Lefaucheur, Alexandre Loupy
it and safety following conversion to belatacept. Methods: We prospectively enrolled 311 kidney transplant recipients from 2007 to 2020 from two referral centers, converted from CNI to belatacept after transplant according to a prespecified protocol. Patients were matched at the time of conversion to patients maintained with CNI, using a optimal matching. The primary endpoint was the death-censored
-
Reverse Phenotypes of Patients with Genetically Confirmed Liddle's Syndrome Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 Granhøj. Jeff, Nøhr. Thomas K, Hinrichs. Gitte R, Rasmussen. Maria, Svenningsen. Per
phenotypic spectrum of genetically confirmed Liddle syndrome is unknown, and some patients may remain undiagnosed and risk inefficient treatment. Here, we used a reverse-phenotyping approach to investigate the Liddle syndrome phenotypic spectrum and genotype-phenotype correlations. Methods: Pubmed, Embase, Scopus, and the Human Gene Mutation Database were searched for articles reporting Liddle syndrome
-
Moving toward Racial Equity in Preemptive Listing for Kidney Transplant in the United States Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 McElroy, Lisa M., Schold, Jesse D.
No abstract available
-
Mechanistic Basis for Intradialytic Hypertension with Hemodialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 Hecking, Manfred, Mussnig, Sebastian, Chazot, Charles
No abstract available
-
Role of Diuretics in Cardiovascular Events and Mortality in Systolic Blood Pressure Intervention Trial: A: Post Hoc: Analysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-25 Shweta Bansal, Robert Boucher, Jincheng Shen, Guo Wei, Glenn M. Chertow, Paul K. Whelton, William C. Cushman, Alfred K. Cheung, Srinivasan Beddhu, on behalf of SPRINT
SPRINT was a randomized, controlled trial of 9361 participants comparing the effects of intensive (systolic BP target <120 mm Hg) versus standard (systolic BP target <140 mm Hg) BP control on a primary composite cardiovascular end point in participants aged 50 years or older with systolic BP of 130–180 mm Hg. In time-varying multivariable Cox analyses, we assessed hazard ratios (HRs) of cardiovascular
-
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in T2DM and CKD: A Secondary Analysis of the SCORED Trial Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-26 Vikas S. Sridhar, Deepak L. Bhatt, Ayodele Odutayo, Michael Szarek, Michael J. Davies, Phillip Banks, Bertram Pitt, Ph. Gabriel Steg, David Z. I. Cherney
versus placebo on this outcome. This exploratory analysis uses laboratory eGFR data, regardless of case report form completion, to assess the effects of sotagliflozin on the predefined kidney composite endpoint in SCORED and additional cardiorenal composite endpoints. Methods: SCORED was a multicenter, randomized trial evaluating cardiorenal outcomes with sotagliflozin versus placebo in 10,584 patients
-
Mechanistic Basis for Intradialytic Hypertension with Hemodialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 Manfred Hecking, Sebastian Mussnig, Charles Chazot
An abstract is unavailable.
-
Moving toward Racial Equity in Preemptive Listing for Kidney Transplant in the United States Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 McElroy, Lisa M., Schold, Jesse D.
No abstract available
-
Kidney after Liver Transplantation for All: Are You Kidneying Me? Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-24 Abhishek Kumar, Hani M. Wadei
An abstract is unavailable.
-
Closure of Dialysis Clinics in the United States in 2021–2023 Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-23 Kalantar-Zadeh, Kamyar, Edwards, Dawn P., Henner, David, Landry, Daniel L., Molony, Donald A., Yerram, Preethi, on behalf of the Medical Advisory Council of the National Forum of ESRD Networks
No abstract available
-
Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-23 Sean J. Barbour, Rosanna Coppo, Lee Er, Evangeline Pillebout, Maria Luisa Russo, Charles E. Alpers, Agnes B. Fogo, Franco Ferrario, J. Charles Jennette, Ian S.D. Roberts, H. Terence Cook, Jie Ding, Baige Su, Xuhui Zhong, Fernando C. Fervenza, Ladan Zand, Licia Peruzzi, Laura Lucchetti, Ritsuko Katafuchi, Yuko Shima, Norishige Yoshikawa, Daisuke Ichikawa, Yusuke Suzuki, Luisa Murer, Robert J. Wyatt
ts. Methods Biopsies from 262 children and 99 adults with IgA vasculitis nephritis (N=361) from 23 centers in North America, Europe, and Asia were independently scored by three pathologists. MEST-C scores were assessed for correlation with eGFR/proteinuria at biopsy. Because most patients (N=309, 86%) received immunosuppression, risk factors for outcomes were evaluated in this group using latent class
-
Evaluation and Measurement Properties of a Patient-Reported Experience Measure for Home Dialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-23 Matthew B. Rivara, David K. Prince, Kerstin K. Leuther, Wael F. Hussein, Rajnish Mehrotra, Todd Edwards, Brigitte Schiller, Donald L. Patrick
thods Using mail and telephone survey modalities, we approached 1372 patients treated with peritoneal dialysis or home hemodialysis for participation. Using the results from completed surveys, we evaluated item calibration by assessing item floor and ceiling effects. We tested three sets of composite scores and used factor analysis to assess model fit for each. We evaluated associations of composite
-
Effect of Remote and Virtual Technology on Home Dialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-22 Susie Q. Lew, Sabrina Milan Manani, Claudio Ronco, Mitchell H. Rosner, James A. Sloand
expected accelerant for telehealth use in the United States. Within nephrology, remote patient monitoring has most often been applied to the care of patients on home dialysis modalities. The effect that remote and virtual technologies have on home dialysis patients, telehealth and health care disparities, and health care providers' workflow changes are discussed here. Moreover, the future use of remote
-
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-15 Jonathan Barratt, Adrian Liew, See Cheng Yeo, Anders Fernström, Sean J. Barbour, C. John Sperati, Russell Villanueva, Ming-Ju Wu, Dazhe Wang, Anna Borodovsky, Prajakta Badri, Elena Yureneva, Ishir Bhan, Daniel Cattran, on behalf of the Cemdisiran Phase 2 Study Investigators and Collaborators
Cemdisiran is an investigational RNA interference therapeutic that suppresses hepatic production of complement component 5 (C5), thereby potentially reducing proteinuria in IgA nephropathy. We evaluated the efficacy and safety of cemdisiran in adult patients with IgA nephropathy at high risk of kidney disease progression. Methods In this phase 2, 36-week, double-blind study, adult patients with IgA
-
Home Dialysis in Patients with Cardiovascular Diseases Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-10 Reaves, Allison C., Weiner, Daniel E., Sarnak, Mark J.
Kidney failure with replacement therapy and cardiovascular disease are frequently comorbid. In patients with kidney failure with replacement therapy, cardiovascular disease is a major contributor to morbidity and mortality. Conventional thrice-weekly in-center dialysis confers risk factors for cardiovascular disease including acute hemodynamic fluctuations and rapid shifts in volume and solute concentration
-
Improving Waitlist Eligibility by Race and Ethnicity Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-12 Wendy Rodgers
An abstract is unavailable.
-
Hemoadsorption Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-15 Bellomo, R, Mehta, RL, Forni, LG, Zarbock, A, Ostermann, M, Ronco, C, on behalf of the Acute Disease Quality Initiative Hemoadsorption Working Group
No abstract available
-
Improving Waitlist Eligibility by Race and Ethnicity Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-12 Rodgers, Wendy
No abstract available
-
Complications of Peritoneal Dialysis Part I: Mechanical Complications Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Xin Bo Justin Cheng, Joanne Bargman
inuation of therapy. Timely diagnosis and resolution are required to minimize preventable modality change to hemodialysis. This review covers mechanical complications, including leaks, PD hydrothorax, hernias, dialysate flow problems, PD-related pain, and changes in respiratory mechanics. Most mechanical complications occur early, either as a result of PD catheter insertion or the introduction of dialysate
-
Protected Time for Program Administration among Nephrology Program Leadership in the United States Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Christina M. Yuan, Brian Y. Young, Maura A. Watson, Amy N. Sussman
ds: Anonymous, on-line survey of all US adult nephrology program directors (March 2023), who forwarded core faculty/associate program director surveys. Questions included protected time in 2022-23 and 2021-22, whether it was sufficient, estimated time needed, and two validated single-item burnout measures (emotional exhaustion and depersonalization). Analysis was descriptive. Results: Program Directors:
-
From Home to Wearable Hemodialysis: Barriers, Progress, and Opportunities Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Matthew B. Rivara, Jonathan Himmelfarb
present barriers for more widespread adoption by a larger proportion of individuals with kidney failure. These limitations include device weight and bulk, ergonomics considerations, technical complexity, vascular access challenges, and limited remote patient monitoring. Recent years have witnessed a resurgence in research and development of prototype wearable kidney replacement devices incorporating
-
Central Body Fat Distribution and Kidney Function after Living Kidney Donation Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Lisa B. Westenberg, Robert A. Pol, Jessica van der Weijden, Martin H. de Borst, Stephan J.L. Bakker, Marco van Londen, on behalf of the Transplant Lines Investigators
distribution measures are associated with long-term kidney function after donor nephrectomy. We hypothesized that higher BMI, waist circumference (WC), and waist-to-height ratio (WHtR) were associated with lower kidney function long term after donation. Methods The study population consisted of living kidney donors. BMI, WC, and WHtR were measured during donor screening. The outcome postdonation kidney
-
Peritoneal Dialysis Care for People with Diabetes, Polycystic Kidney Disease, or Advanced Liver Disease Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Agarwal, Shailesh, Gillis, Laura, Wilkie, Martin
People treated with peritoneal dialysis (PD) often have complicating conditions that require careful management. Three such conditions are reviewed in this article – diabetes mellitus, polycystic kidney disease (PKD) and chronic liver disease. Each of these conditions requires an understanding of both its impact on the delivery of the PD, as well as the impact of the PD on the condition itself. With
-
Complications of Peritoneal Dialysis Part II: Nonmechanical Complications Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Xin Bo Justin Cheng, Joanne Bargman
treatment, non-infectious, non-mechanical complications often present late in patients that are established on PD. In this review, we first discuss abnormal-appearing drained dialysate, including hemoperitoneum, chyloperitoneum and non-infectious cloudy dialysate. The underlying cause is frequently unrelated to PD. We then discuss encapsulating peritoneal sclerosis, a rare complication of PD. Lastly
-
Evaluating ApoL1 Genetic Testing Policy Options for Transplant Centers: A Delphi Consensus Panel Project with Stakeholders Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Tristan McIntosh, Heidi Walsh, Kari Baldwin, Ana Iltis, Sumit Mohan, Deirdre Sawinski, Melody Goodman, James M. DuBois
for ApoL1 risk variants. Transplant programs have highly variable ApoL1 testing practices and need guidance on essential ApoL1 clinical policy questions. Methods We conducted a Delphi consensus panel focused on ApoL1 clinical policy questions, including who gets tested, who decides whether testing occurs, how test results are shared, who receives test results, and how test results are used. A total
-
The Association of Intra-Abdominal Adhesions with Peritoneal Dialysis Catheter-Related Complications Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Mohammad Azfar Qureshi, Serban Maierean, John H. Crabtree, Alix Clarke, Sean Armstrong, Rachel Fissell, Arsh K. Jain, Sarbjit V. Jassal, Susie L. Hu, Peter Kennealey, Scott Liebman, Brendan McCormick, Bogdan Momciu, Robert P. Pauly, Beth Pellegrino, Jeffrey Perl, James L. Jr. Pirkle, Troy J. Plumb, Rebecca Seshasai, Ankur Shah, Nikhil Shah, Jenny Shen, Gurmukteshwar Singh, Karthik Tennankore, Jaime
s. Patients were grouped based on the presence of adhesions observed during catheter insertion. The primary outcome was the composite of PD never starting, termination of PD, or the need for an invasive procedure caused by flow restriction or abdominal pain. Results Seven hundred and fifty-eight individuals were enrolled, of whom 201 (27%) had adhesions during laparoscopic PD catheter insertion. The
-
Patient Training and Patient Safety in Home Hemodialysis Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Platnich, Jaye M., Pauly, Robert P.
The success of a home hemodialysis (HD) program depends largely on a patient safety framework and the risk tolerance of a home dialysis program. Dialysis treatments require operators to perform dozens of steps repeatedly and reliably in a complex procedure. For home HD, those operators are patients themselves or their care partners, so attention to safety and risk mitigation is front of mind. While
-
The Burden of Home Dialysis: An Overlooked Challenge Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-08 Emilie Trinh, Karine Manera, Nicole Scholes-Robertson, Jenny I. Shen
nd safely perform dialysis at home, physical symptoms, impairment of life participation, psychosocial challenges, and care partner burnout. Overlooking or failing to address these issues may lead to adverse events that negatively impact health and quality of life and reduce longevity of home dialysis. This paper will explore aspects of home dialysis associated with burden, emphasize the need for increased
-
Safety of Antidepressant Medications to Treat Comorbid Depression in CKD: Are We There Yet? Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-04 S. Susan Hedayati
An abstract is unavailable.
-
Post-Trial Follow-Up of Kidney Outcomes in SPRINT: Some Reassurance, Some Unanswered Questions Clin. J. Am. Soc. Nephrol. (IF 9.8) Pub Date : 2024-01-03 Ku, Elaine, Sarnak, Mark
No abstract available